Q (haiku): Is BRCA1 promoter methylation associated with decreased BRCA1 mRNA expression in ovarian cancer?

▶ read_guide
{
 "uri": "cbioportal://gene-expression-guide"
}

▶ search_oncotree
{
 "search_term": "ovarian cancer"
}

◀ result
# Gene Expression Analysis Guide

This guide covers continuous-value genomic data: gene **expression**, **copy number** values, **methylation**, and related profile types. Mutation/CNA/SV *frequency* analysis lives in `cbioportal://mutation-frequency-guide`.

## Where this data lives

Continuous per-sample-per-gene values are stored in `genetic_alteration_derived`:

| Column | Description |
|---|---|
| `sample_unique_id` | `<study>_<sample_stable_id>` |
| `cancer_study_identifier` | study scope |
| `hugo_gene_symbol` | gene |
| `profile_type` | which assay/normalization (see below) |
| `alteration_value` | the actual value — stored as Nullable(String); cast with `toFloat64OrNull` |

`alteration_value` is a string because the same column hosts many different value scales. The `''` and `'NA'` sentinels mean "missing"; always filter them out and use `toFloat64OrNull(alteration_value) IS NOT NULL` for downstream math.

## Discovering profile types for a study

Different studies expose different profile types depending on what assays were run and how the data was normalized. Always check what a specific study supports before picking one:

```sql
SELECT DISTINCT profile_type
FROM genetic_alteration_derived
WHERE cancer_study_identifier = 'brca_metabric'
ORDER BY profile_type;
```

Common values across the public portal:

| Family | Profile types |
|---|---|
| mRNA expression | `rna_seq_v2_mrna`, `rna_seq_v2_mrna_median_Zscores`, `rna_seq_v2_mrna_median_all_sample_Zscores` (TCGA PanCancer Atlas), `mrna`, `mrna_median_Zscores`, `mrna_seq_v2_rsem`, `mrna_seq_v2_rsem_Zscores`, `mrna_seq_cpm`, `mrna_seq_fpkm`, `mrna_U133`, `mrna_outliers` |
| Copy number (continuous) | `cna`, `linear_CNA`, `log2CNA`, `cna_consensus`, `cna_rae`, `gistic` |
| Methylation | `methylation_hm27`, `methylation_hm450`, `methylation_epic`, `methylation_promoters_rrbs` |
| miRNA | `mirna`, `mirna_median_Zscores` |
| Protein | `protein_quantification`, `protein_level`, `RPPA` |

**Z-score vs raw choice.** When the user asks "is X correlated with Y", either works for Spearman (rank-based) — Pearson would care. Default to the non-Z-score variant if both exist, and call out which one in the response.

## Canonical recipe — Spearman correlation between two genes

```sql
SELECT *
FROM gene_pair_coexpression(
    study        = 'brca_metabric',
    gene_a       = 'TP53',
    gene_b       = 'MYC',
    profile_type = 'mrna'
);
```

Returns one row: `(gene_a, gene_b, profile_type, spearman_correlation, num_samples)`.

- `spearman_correlation` in [−1, 1]; `NULL` when fewer than 3 valid paired samples.
- Mirrors cbioportal-backend's `ClickhouseCoExpressionMapper.getCoExpressions`, simplified to a pair lookup (the backend computes one ref gene vs ALL other genes for the coexpression page; here the agent asks about a specific pair).

### Verified examples

| Study | gene_a | gene_b | profile_type | spearman | n |
|---|---|---|---|---|---|
| `brca_metabric` | TP53 | MYC | `mrna` | 0.118 | 1980 |
|  … (4931 more chars)

◀ result
{"result":[{"code":"BTBEOV","name":"Brenner Tumor, Benign","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > BTOV > BTBEOV"},{"code":"BTBOV","name":"Brenner Tumor, Borderline","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > BTOV > BTBOV"},{"code":"BTMOV","name":"Brenner Tumor, Malignant","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > BTOV > BTMOV"},{"code":"BTOV","name":"Brenner Tumor","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > BTOV"},{"code":"CCBOV","name":"Clear Cell Borderline Ovarian Tumor","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > CCBOV"},{"code":"CCOV","name":"Clear Cell Ovarian Cancer","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > CCOV"},{"code":"EBOV","name":"Endometrioid Borderlin Ovarian Tumor","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > EBOV"},{"code":"EOV","name":"Endometrioid Ovarian Cancer","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > EOV"},{"code":"HGONEC","name":"High-Grade Neuroendocrine Carcinoma of the Ovary","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OOVC > HGONEC"},{"code":"HGSFT","name":"High-Grade Serous Fallopian Tube Cancer","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OOVC > HGSFT"},{"code":"HGSOC","name":"High-Grade Serous Ovarian Cancer","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > SOC > HGSOC"},{"code":"LGSOC","name":"Low-Grade Serous Ovarian Cancer","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > SOC > LGSOC"},{"code":"MBOV","name":"Mucinous Borderline Ovarian Tumor","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > MBOV"},{"code":"MOV","name":"Mucinous Ovarian Cancer","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > MOV"},{"code":"MXOV","name":"Mixed Ovarian Carcinoma","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > MXOV"},{"code":"OCNOS","name":"Ovarian Choriocarcinoma, NOS","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OOVC > OCNOS"},{"code":"OCS","name":"Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OVT > OCS"},{"code":"OOVC","name":"Ovarian Cancer, Other","score":65,"mainType":"Ovarian Cancer","tissue":"Ovary/Fallopian Tube","hierarchy":"OVARY > OOVC"},{"code":"OSMAD","name":"Ovarian Seromucinous Adenoma","score":65 … (1077 more chars)

▶ list_studies
{
 "search": "ovarian",
 "limit": 20,
 "verbose": true
}

◀ result
{"result":[{"cancer_study_identifier":"msk_met_2021","name":"MSK MetTropism (MSK, Cell 2021)","description":"MSK-MET (Memorial Sloan Kettering - Metastatic Events and Tropisms) is a pan-cancer cohort of tumor genomic and clinical outcome data from 25,000 patients. The dataset identifies associations between tumor genomic alterations and patterns of metastatic dissemination across 50 tumor types; showing that chromosomal instability is strongly correlated with metastatic burden in some tumor types, like prostate and lung adenocarcinomas and HR+/HER2+ breast ductal carcinoma, but not in others, such as colorectal MSS, pancreatic adenocarcinoma and high-grade serous ovarian cancer. The study also identifies somatic alterations associated with increased metastatic burden and routes of metastatic spread. Our data offers a resource for the investigation of the biologic basis for metastatic spread and highlights the role of chromosomal instability in cancer progression. This data is available under the <a href=\"https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en\">Creative Commons BY-NC-ND 4.0 license</a>.","type_of_cancer_id":"mixed","sample_count":25775,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=msk_met_2021"},{"cancer_study_identifier":"ov_tcga","name":"Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)","description":"TCGA Ovarian Serous Cystadenocarcinoma. Source data from <A HREF=\"http://gdac.broadinstitute.org/runs/stddata__2016_01_28/data/OV/20160128/\">GDAC Firehose</A>. Previously known as TCGA Provisional.","type_of_cancer_id":"hgsoc","sample_count":617,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=ov_tcga"},{"cancer_study_identifier":"hgsoc_tcga_gdc","name":"High-Grade Serous Ovarian Cancer (TCGA GDC, 2025)","description":"TCGA High-Grade Serous Ovarian Cancer. Source data from <A HREF=\"https://gdc.cancer.gov\">NCI GDC</A> and generated in Aug 2025 using <A HREF=\"https://cda.readthedocs.io/en/latest/\">Cancer Data Aggregator</A>.","type_of_cancer_id":"hgsoc","sample_count":604,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=hgsoc_tcga_gdc"},{"cancer_study_identifier":"ov_tcga_pan_can_atlas_2018","name":"Ovarian Serous Cystadenocarcinoma (TCGA, PanCancer Atlas)","description":"Ovarian Serous Cystadenocarcinoma TCGA PanCancer data. The original data is <a href=\"https://gdc.cancer.gov/about-data/publications/pancanatlas\">here</a>. The publications are <a href=\"https://www.cell.com/pb-assets/consortium/pancanceratlas/pancani3/index.html\">here</a>.","type_of_cancer_id":"hgsoc","sample_count":585,"has_guide":true,"url":"https://www.cbioportal.org/study/summary?id=ov_tcga_pan_can_atlas_2018"},{"cancer_study_identifier":"ovary_geomx_gray_foundation_2024","name":"Ovarian Cancer (Gray Foundation, Cancer Discov 2024)","description":"Microregion transcriptomic data (GeoMx) and multiplex imaging (CyCIF) for High-Grade Serous ovarian Cancer Cases (HGSOC). This resou … (4038 more chars)

▶ get_study_guide
{
 "study_id": "ov_tcga_pan_can_atlas_2018"
}

◀ result
# Ovarian Serous Cystadenocarcinoma (TCGA, PanCancer Atlas)

**Study ID:** `ov_tcga_pan_can_atlas_2018`

See `_tcga_pancan_template.md` for common TCGA clinical attributes.

## Study-Specific Attributes

### Histology
| Attribute | Description | Values (samples) |
|-----------|-------------|--------|
| `GRADE` | Histologic grade | G3 400, G2 65, GX 7, G1 5, GB 2, G4 1, blank 105 |
| `CANCER_TYPE_DETAILED` | Histology | Serous Ovarian Cancer (all 585) |

### Not available in this study
- **Platinum sensitivity and residual disease**: no treatment-response or surgical-outcome attributes. Survival (`OS_*`, `PFS_*`, `DFS_*`, `DSS_*`) is the only outcome data.
- **BRCA / HRD status**: no clinical status attributes. Derive BRCA1/BRCA2 status from mutation (somatic calls only) and CNA data; there is no HRD score.
- `AJCC_PATHOLOGIC_TUMOR_STAGE` is blank for all samples. `SUBTYPE` is `OV` (177) or blank (408) and carries no molecular subtype.

## Key Genes
| Gene | Frequency | Notes |
|------|-----------|-------|
| TP53 | ~96% | Near-universal in high-grade serous |
| BRCA1 | ~10% germline | PARP inhibitor sensitivity |
| BRCA2 | ~6% germline | PARP inhibitor sensitivity |
| NF1 | ~4% | RAS pathway |
| RB1 | ~2% | Cell cycle |
| CDK12 | ~3% | DNA repair |

## Notes
- High-grade serous ovarian cancer (HGSOC) is genomically distinct from other ovarian subtypes
- TP53 is mutated in virtually all HGSOC
- BRCA1/2 mutations (germline or somatic) predict PARP inhibitor response
- HRD score predicts platinum and PARP sensitivity even without BRCA mutation
- Copy number alterations more prominent than mutations (except TP53)


▶ clickhouse_run_select_query
{
 "query": "SELECT DISTINCT profile_type
FROM genetic_alteration_derived
WHERE cancer_study_identifier = 'ov_tcga_pan_can_atlas_2018'
ORDER BY profile_type
LIMIT 50"
}

◀ result
{"rows":[{"profile_type":"gistic"},{"profile_type":"log2CNA"},{"profile_type":"protein_quantification"},{"profile_type":"protein_quantification_zscores"},{"profile_type":"rna_seq_v2_mrna"},{"profile_type":"rna_seq_v2_mrna_median_Zscores"},{"profile_type":"rna_seq_v2_mrna_median_all_sample_Zscores"},{"profile_type":"rppa"},{"profile_type":"rppa_Zscores"}]}

▶ clickhouse_run_select_query
{
 "query": "SELECT cancer_study_identifier, DISTINCT profile_type
FROM genetic_alteration_derived
WHERE cancer_study_identifier IN ('ov_tcga', 'hgsoc_tcga_gdc', 'ov_tcga_pub')
  AND profile_type LIKE '%methyl%'
GROUP BY cancer_study_identifier, profile_type
ORDER BY cancer_study_identifier",
 "max_rows": 30
}

◀ result
{"error_message":"Query execution failed: HTTPDriver for https://dl96orhu96.us-east-1.aws.clickhouse.cloud:8443 received ClickHouse error code 47\n Code: 47. DB::Exception: Unknown expression identifier `DISTINCT` in scope SELECT cancer_study_identifier, `DISTINCT` AS profile_type FROM genetic_alteration_derived WHERE (cancer_study_identifier IN ('ov_tcga', 'hgsoc_tcga_gdc', 'ov_tcga_pub')) AND (profile_type LIKE '%methyl%') GROUP BY cancer_study_identifier, profile_type ORDER BY cancer_study_identifier ASC. Maybe you meant: ['_distance']. (UNKNOWN_IDENTIFIER) (version 26.4.1.2359 (official build))\n"}

▶ clickhouse_run_select_query
{
 "query": "SELECT cancer_study_identifier, profile_type
FROM genetic_alteration_derived
WHERE cancer_study_identifier IN ('ov_tcga', 'hgsoc_tcga_gdc', 'ov_tcga_pub')
  AND profile_type LIKE '%methyl%'
GROUP BY cancer_study_identifier, profile_type
ORDER BY cancer_study_identifier",
 "max_rows": 30
}

◀ result
{"rows":[{"cancer_study_identifier":"ov_tcga","profile_type":"methylation_hm27"},{"cancer_study_identifier":"ov_tcga_pub","profile_type":"methylation_hm27"}]}

▶ clickhouse_run_select_query
{
 "query": "-- Check what BRCA1 data is available in ov_tcga
SELECT profile_type, COUNT(*) AS sample_count
FROM genetic_alteration_derived
WHERE cancer_study_identifier = 'ov_tcga'
  AND hugo_gene_symbol = 'BRCA1'
  AND alteration_value NOT IN ('', 'NA')
  AND toFloat64OrNull(alteration_value) IS NOT NULL
GROUP BY profile_type
ORDER BY profile_type",
 "max_rows": 10
}

◀ result
{"rows":[{"profile_type":"gistic","sample_count":579},{"profile_type":"linear_CNA","sample_count":579},{"profile_type":"methylation_hm27","sample_count":592},{"profile_type":"mrna","sample_count":558},{"profile_type":"mrna_U133","sample_count":535},{"profile_type":"mrna_U133_Zscores","sample_count":535},{"profile_type":"mrna_U133_all_sample_Zscores","sample_count":535},{"profile_type":"mrna_median_Zscores","sample_count":558},{"profile_type":"mrna_median_all_sample_Zscores","sample_count":558},{"profile_type":"protein_quantification","sample_count":21}],"truncated":true,"returned_rows":10,"note":"Result truncated to 10 rows; more rows matched but the exact total is unknown because the query was capped during execution for efficiency. Narrow the query (add a LIMIT, aggregate, or filter) or pass a larger max_rows (up to 10000) to see more."}

▶ clickhouse_run_select_query
{
 "query": "-- Spearman correlation between BRCA1 methylation and BRCA1 mRNA expression
WITH methylation AS (
    SELECT sample_unique_id, toFloat64OrNull(alteration_value) AS methyl_value
    FROM genetic_alteration_derived
    WHERE cancer_study_identifier = 'ov_tcga'
      AND hugo_gene_symbol = 'BRCA1'
      AND profile_type = 'methylation_hm27'
      AND alteration_value NOT IN ('', 'NA')
      AND toFloat64OrNull(alteration_value) IS NOT NULL
),
expression AS (
    SELECT sample_unique_id, toFloat64OrNull(alteration_value) AS expr_value
    FROM genetic_alteration_derived
    WHERE cancer_study_identifier = 'ov_tcga'
      AND hugo_gene_symbol = 'BRCA1'
      AND profile_type = 'mrna'
      AND alteration_value NOT IN ('', 'NA')
      AND toFloat64OrNull(alteration_value) IS NOT NULL
)
SELECT 
    rankCorr(m.methyl_value, e.expr_value) AS spearman_correlation,
    COUNT(*) AS num_samples,
    ROUND(AVG(m.methyl_value), 3) AS mean_methylation,
    ROUND(AVG(e.expr_value), 3) AS mean_expression,
    ROUND(MIN(m.methyl_value), 3) AS min_methylation,
    ROUND(MAX(m.methyl_value), 3) AS max_methylation
FROM methylation m
INNER JOIN expression e USING (sample_unique_id)",
 "max_rows": 10
}

◀ result
{"rows":[{"spearman_correlation":-0.40336141757343147,"num_samples":550,"mean_methylation":0.129,"mean_expression":-1.746,"min_methylation":0.011,"max_methylation":0.955}]}

▶ clickhouse_run_select_query
{
 "query": "-- Stratify by methylation level (high vs low)
WITH methylation AS (
    SELECT sample_unique_id, toFloat64OrNull(alteration_value) AS methyl_value
    FROM genetic_alteration_derived
    WHERE cancer_study_identifier = 'ov_tcga'
      AND hugo_gene_symbol = 'BRCA1'
      AND profile_type = 'methylation_hm27'
      AND alteration_value NOT IN ('', 'NA')
      AND toFloat64OrNull(alteration_value) IS NOT NULL
),
expression AS (
    SELECT sample_unique_id, toFloat64OrNull(alteration_value) AS expr_value
    FROM genetic_alteration_derived
    WHERE cancer_study_identifier = 'ov_tcga'
      AND hugo_gene_symbol = 'BRCA1'
      AND profile_type = 'mrna'
      AND alteration_value NOT IN ('', 'NA')
      AND toFloat64OrNull(alteration_value) IS NOT NULL
),
combined AS (
    SELECT m.methyl_value, e.expr_value,
           CASE WHEN m.methyl_value >= 0.5 THEN 'High Methylation (≥0.5)' 
                ELSE 'Low Methylation (<0.5)' END AS methyl_group
    FROM methylation m
    INNER JOIN expression e USING (sample_unique_id)
)
SELECT 
    methyl_group,
    COUNT(*) AS sample_count,
    ROUND(AVG(methyl_value), 3) AS mean_methylation,
    ROUND(MEDIAN(expr_value), 3) AS median_expression,
    ROUND(AVG(expr_value), 3) AS mean_expression,
    ROUND(QUANTILE(0.25)(expr_value), 3) AS q25_expression,
    ROUND(QUANTILE(0.75)(expr_value), 3) AS q75_expression
FROM combined
GROUP BY methyl_group
ORDER BY methyl_group",
 "max_rows": 10
}

◀ result
{"error_message":"Query execution failed: HTTPDriver for https://dl96orhu96.us-east-1.aws.clickhouse.cloud:8443 received ClickHouse error code 63\n Code: 63. DB::Exception: Unknown aggregate function MEDIAN. Maybe you meant: ['median','medianDD']. (UNKNOWN_AGGREGATE_FUNCTION) (version 26.4.1.2359 (official build))\n"}

▶ clickhouse_run_select_query
{
 "query": "-- Stratify by methylation level (high vs low)
WITH methylation AS (
    SELECT sample_unique_id, toFloat64OrNull(alteration_value) AS methyl_value
    FROM genetic_alteration_derived
    WHERE cancer_study_identifier = 'ov_tcga'
      AND hugo_gene_symbol = 'BRCA1'
      AND profile_type = 'methylation_hm27'
      AND alteration_value NOT IN ('', 'NA')
      AND toFloat64OrNull(alteration_value) IS NOT NULL
),
expression AS (
    SELECT sample_unique_id, toFloat64OrNull(alteration_value) AS expr_value
    FROM genetic_alteration_derived
    WHERE cancer_study_identifier = 'ov_tcga'
      AND hugo_gene_symbol = 'BRCA1'
      AND profile_type = 'mrna'
      AND alteration_value NOT IN ('', 'NA')
      AND toFloat64OrNull(alteration_value) IS NOT NULL
),
combined AS (
    SELECT m.methyl_value, e.expr_value,
           CASE WHEN m.methyl_value >= 0.5 THEN 'High Methylation (≥0.5)' 
                ELSE 'Low Methylation (<0.5)' END AS methyl_group
    FROM methylation m
    INNER JOIN expression e USING (sample_unique_id)
)
SELECT 
    methyl_group,
    COUNT(*) AS sample_count,
    ROUND(AVG(methyl_value), 3) AS mean_methylation,
    ROUND(quantile(0.5)(expr_value), 3) AS median_expression,
    ROUND(AVG(expr_value), 3) AS mean_expression,
    ROUND(quantile(0.25)(expr_value), 3) AS q25_expression,
    ROUND(quantile(0.75)(expr_value), 3) AS q75_expression
FROM combined
GROUP BY methyl_group
ORDER BY methyl_group",
 "max_rows": 10
}

◀ result
{"rows":[{"methyl_group":"High Methylation (≥0.5)","sample_count":62,"mean_methylation":0.757,"median_expression":-3.209,"mean_expression":-3.21,"q25_expression":-3.528,"q75_expression":-2.877},{"methyl_group":"Low Methylation (<0.5)","sample_count":488,"mean_methylation":0.05,"median_expression":-1.523,"mean_expression":-1.56,"q25_expression":-1.967,"q75_expression":-1.143}]}

▶ resolve_and_route
{
 "studyIds": [
  "ov_tcga"
 ]
}

◀ result
{"success":true,"message":"Found 1 study. Use the metadata to call the appropriate navigation tool(s).","data":{"totalCount":1,"studiesWithMetadata":[{"studyId":"ov_tcga","name":"Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)","sampleCount":617,"studyViewUrl":"https://www.cbioportal.org/study?id=ov_tcga","metadata":{"clinicalAttributeIds":["AGE","AJCC_PATHOLOGIC_TUMOR_STAGE","AJCC_STAGING_EDITION","CANCER_TYPE","CANCER_TYPE_DETAILED","CLINICAL_STAGE","CLIN_M_STAGE","CLIN_N_STAGE","CLIN_T_STAGE","DAYS_TO_COLLECTION","DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS","DAYS_TO_PATIENT_PROGRESSION_FREE","DAYS_TO_SPECIMEN_COLLECTION","DAYS_TO_TUMOR_PROGRESSION","DFS_MONTHS","DFS_STATUS","DISEASE_CODE","ECOG_SCORE","ETHNICITY","EXTRANODAL_INVOLVEMENT","FORM_COMPLETION_DATE","FRACTION_GENOME_ALTERED","GRADE","HISTOLOGICAL_DIAGNOSIS","HISTORY_NEOADJUVANT_TRTYN","HISTORY_OTHER_MALIGNANCY","ICD_10","ICD_O_3_HISTOLOGY","ICD_O_3_SITE","INFORMED_CONSENT_VERIFIED","INITIAL_PATHOLOGIC_DX_YEAR","IS_FFPE","JEWISH_RELIGION_HERITAGE_INDICATOR","KARNOFSKY_PERFORMANCE_SCORE","LONGEST_DIMENSION","LYMPHOVASCULAR_INVASION_INDICATOR","METHOD_OF_INITIAL_SAMPLE_PROCUREMENT","METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER","METHOD_OF_SAMPLE_PROCUREMENT","MUTATION_COUNT","NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT","OCT_EMBEDDED","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","OTHER_METHOD_OF_SAMPLE_PROCUREMENT","OTHER_PATIENT_ID","OTHER_SAMPLE_ID","PATHOLOGY_REPORT_FILE_NAME","PATHOLOGY_REPORT_UUID","PATH_M_STAGE","PATH_N_STAGE","PATH_T_STAGE","PERFORMANCE_STATUS_TIMING","PHARMACEUTICAL_TX_ADJUVANT","PRIMARY_SITE","PROJECT_CODE","PROSPECTIVE_COLLECTION","RACE","RADIATION_TREATMENT_ADJUVANT","RESIDUAL_TUMOR","RETROSPECTIVE_COLLECTION","SAMPLE_COUNT","SAMPLE_INITIAL_WEIGHT","SAMPLE_TYPE","SAMPLE_TYPE_ID","SEX","SHORTEST_DIMENSION","SOMATIC_STATUS","SPECIMEN_CURRENT_WEIGHT","SPECIMEN_FREEZING_METHOD","SPECIMEN_SECOND_LONGEST_DIMENSION","STAGE_OTHER","TIME_BETWEEN_CLAMPING_AND_FREEZING","TIME_BETWEEN_EXCISION_AND_FREEZING","TISSUE_SOURCE_SITE","TMB_NONSYNONYMOUS","TREATMENT_OUTCOME_FIRST_COURSE","TUMOR_STATUS","TUMOR_TISSUE_SITE","VASCULAR_INVASION_INDICATOR","VIAL_NUMBER"],"molecularProfileIds":["ov_tcga_gistic","ov_tcga_linear_CNA","ov_tcga_methylation_hm27","ov_tcga_mrna","ov_tcga_mrna_U133","ov_tcga_mrna_U133_Zscores","ov_tcga_mrna_U133_all_sample_Zscores","ov_tcga_mrna_median_Zscores","ov_tcga_mrna_median_all_sample_Zscores","ov_tcga_mutations","ov_tcga_protein_quantification","ov_tcga_protein_quantification_zscores","ov_tcga_rna_seq_v2_mrna","ov_tcga_rna_seq_v2_mrna_median_Zscores","ov_tcga_rna_seq_v2_mrna_median_all_sample_Zscores","ov_tcga_rppa","ov_tcga_rppa_Zscores"],"genericAssayProfiles":["ov_tcga_phosphoprotein_quantification"],"heatmapProfileIds":["ov_tcga_methylation_hm27","ov_tcga_mrna_U133_Zscores","ov_tcga_mrna_U133_all_sample_Zscores","ov_tcga_mrna_median_Zscores","ov_tcga_mrna_median_all_sample_Zscores","ov_tcga_protein_quantification_zscores","ov_tcga_rna_seq_v2_mrna_medi … (256 more chars)

▶ navigate_to_group_comparison
{
 "studyIds": [
  "ov_tcga"
 ],
 "groups": [
  {
   "name": "High BRCA1 Methylation (≥0.5)",
   "studyViewFilter": {
    "genomicDataFilters": [
     {
      "hugoGeneSymbol": "BRCA1",
      "profileType": "methylation_hm27",
      "values": [
       {
        "start": 0.5,
        "end": 999
       }
      ]
     }
    ]
   }
  },
  {
   "name": "Low BRCA1 Methylation (<0.5)",
   "studyViewFilter": {
    "genomicDataFilters": [
     {
      "hugoGeneSymbol": "BRCA1",
      "profileType": "methylation_hm27",
      "values": [
       {
        "start": 0,
        "end": 0.5
       }
      ]
     }
    ]
   }
  }
 ],
 "tab": "mrna"
}

◀ result
{"success":true,"message":"Navigating to https://www.cbioportal.org/comparison/mrna?comparisonId=6ab7f4eec2115c492d885145","url":"https://www.cbioportal.org/comparison/mrna?comparisonId=6ab7f4eec2115c492d885145","data":{"description":"Group comparison (2 custom groups)","studies":["ov_tcga"],"totalGroups":2,"groups":[{"name":"High BRCA1 Methylation (≥0.5)","sampleCount":67},{"name":"Low BRCA1 Methylation (<0.5)","sampleCount":525}],"studyViewUrl":"https://www.cbioportal.org/study?id=ov_tcga","groupUrls":[{"groupName":"High BRCA1 Methylation (≥0.5)","url":"https://www.cbioportal.org/study?id=ov_tcga#filterJson=%7B%22genomicDataFilters%22%3A%5B%7B%22hugoGeneSymbol%22%3A%22BRCA1%22%2C%22profileType%22%3A%22methylation_hm27%22%2C%22values%22%3A%5B%7B%22start%22%3A0.5%2C%22end%22%3A999%7D%5D%7D%5D%7D"},{"groupName":"Low BRCA1 Methylation (<0.5)","url":"https://www.cbioportal.org/study?id=ov_tcga#filterJson=%7B%22genomicDataFilters%22%3A%5B%7B%22hugoGeneSymbol%22%3A%22BRCA1%22%2C%22profileType%22%3A%22methylation_hm27%22%2C%22values%22%3A%5B%7B%22start%22%3A0%2C%22end%22%3A0.5%7D%5D%7D%5D%7D"}],"pageDescription":"mRNA expression for all genes compared across High BRCA1 Methylation (≥0.5) (67) vs Low BRCA1 Methylation (<0.5) (525)."}}

▶ navigate_to_results_view
{
 "studyIds": [
  "ov_tcga"
 ],
 "genes": [
  "BRCA1"
 ],
 "tab": "oncoprint",
 "oncoprintHeatmapTracks": [
  {
   "molecularProfileId": "ov_tcga_methylation_hm27",
   "entities": [
    "BRCA1"
   ]
  },
  {
   "molecularProfileId": "ov_tcga_mrna",
   "entities": [
    "BRCA1"
   ]
  }
 ]
}

◀ result
{"success":true,"message":"Navigating to https://www.cbioportal.org/results/oncoprint?cancer_study_list=ov_tcga&gene_list=BRCA1&case_set_id=ov_tcga_all&heatmap_track_groups=ov_tcga_methylation_hm27%2CBRCA1%3Bov_tcga_mrna%2CBRCA1","url":"https://www.cbioportal.org/results/oncoprint?cancer_study_list=ov_tcga&gene_list=BRCA1&case_set_id=ov_tcga_all&heatmap_track_groups=ov_tcga_methylation_hm27%2CBRCA1%3Bov_tcga_mrna%2CBRCA1","data":{"studyIds":["ov_tcga"],"studies":[{"studyId":"ov_tcga","name":"Ovarian Serous Cystadenocarcinoma (TCGA, Firehose Legacy)","sampleCount":617}],"genes":["BRCA1"],"caseSetId":"ov_tcga_all","oncoprintHeatmapTracks":[{"molecularProfileId":"ov_tcga_methylation_hm27","entities":["BRCA1"]},{"molecularProfileId":"ov_tcga_mrna","entities":["BRCA1"]}],"pageDescription":"Visual summary of alterations in queried genes across samples."}}

═ answer (success)
## Summary: BRCA1 Promoter Methylation and mRNA Expression in Ovarian Cancer

**Yes, BRCA1 promoter methylation is significantly associated with decreased BRCA1 mRNA expression in ovarian cancer.**

### Key Findings (TCGA Ovarian Cancer, 550 samples with both data types):

| Metric | Value |
|--------|-------|
| **Spearman Correlation** | **−0.40** |
| **Sample Size** | 550 samples |
| **Direction** | Negative (higher methylation → lower expression) |

### Expression by Methylation Level:

| Methylation Group | Samples | Mean Methylation | Median Expression | IQR (Q1–Q3) |
|---|---|---|---|---|
| **High (≥0.5)** | 62 | 0.76 | −3.21 | −3.53 to −2.88 |
| **Low (<0.5)** | 488 | 0.05 | −1.52 | −1.97 to −1.14 |

The **1.7-fold difference in median expression** (−3.21 vs −1.52) between high and low methylation groups demonstrates a substantial functional impact: high BRCA1 methylation is associated with markedly reduced BRCA1 mRNA expression.

### Interactive Visualizations

Explore the data in cBioPortal:

1. **[Compare mRNA expression by BRCA1 methylation level](https://www.cbioportal.org/comparison/mrna?comparisonId=6ab7f4eec2115c492d885145)** — Group comparison showing all gene expression differences (focus on BRCA1 row). Includes statistical tests and clinical outcome stratification.

2. **[View BRCA1 methylation and expression heatmap](https://www.cbioportal.org/results/oncoprint?cancer_study_list=ov_tcga&gene_list=BRCA1&case_set_id=ov_tcga_all&heatmap_track_groups=ov_tcga_methylation_hm27%2CBRCA1%3Bov_tcga_mrna%2CBRCA1)** — OncoPrint with stacked heatmap tracks showing methylation (top) and expression (bottom) for all 617 ovarian samples. Scrolling across samples visually demonstrates the inverse relationship.

3. **[View full study cohort](https://www.cbioportal.org/study?id=ov_tcga)** — TCGA ovarian cohort summary; use StudyView filters to isolate high/low methylation subgroups and explore clinical outcomes.

### Biological Interpretation

This negative correlation is consistent with **methylation-mediated gene silencing**: elevated BRCA1 promoter methylation (>0.5 β-value) suppresses transcription, reducing mRNA levels. This mechanism may confer PARP inhibitor sensitivity even in the absence of BRCA1 mutations — a clinically important distinction for treatment planning.